In Vitro Susceptibility Testing of Tedizolid against Nontuberculous Mycobacteria
- 1 June 2017
- journal article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 55 (6), 1747-1754
- https://doi.org/10.1128/jcm.00274-17
Abstract
Tedizolid is a new oxazolidinone with improved in vitro and intracellular potency against Mycobacterium tuberculosis , including multidrug-resistant strains, and some species of nontuberculous mycobacteria (NTM) compared with that of linezolid. Using the current Clinical and Laboratory Standards Institute (CLSI)-recommended method of broth microdilution, susceptibility testing of 170 isolates of rapidly growing mycobacteria showed equivalent or lower (1- to 8-fold) MIC 50 and/or MIC 90 values for tedizolid compared with that for linezolid. The tedizolid MIC 90 values for 81 isolates of M. abscessus subsp. abscessus and 12 isolates of M. abscessus subsp. massiliense were 8 μg/ml and 4 μg/ml, respectively, compared with linezolid MIC 90 values of 32 μg/ml for both. The MIC 90 values for 20 isolates of M. fortuitum were 2 μg/ml for tedizolid and 4 μg/ml for linezolid. Twenty-two isolates of M. chelonae had tedizolid and linezolid MIC 90 s of 2 μg/ml and 16 μg/ml, respectively. One hundred forty-two slowly growing NTM, including 7/7 M. marinum , 7/7 M. kansasii , and 7/11 of other less commonly isolated species, had tedizolid MICs of ≤1 μg/ml and linezolid MICs of ≤4 μg/ml. One hundred isolates of Mycobacterium avium complex and eight M. simiae isolates had tedizolid MIC 50 s of 8 μg/ml and linezolid MIC 50 s 32 and 64 μg/ml, respectively. Nine M. arupense isolates had MIC 50 s of 4 μg/ml and 16 μg/ml for tedizolid and linezolid, respectively. These findings demonstrate a greater in vitro potency of tedizolid than linezolid against NTM and suggest that an evaluation of tedizolid as a potential treatment agent for infections caused by selected NTM is warranted.Keywords
Funding Information
- Merck (NA)
This publication has 19 references indexed in Scilit:
- Intracellular activity of tedizolid phosphate and ACH-702 versus Mycobacterium tuberculosis infected macrophagesAnnals of Clinical Microbiology and Antimicrobials, 2014
- Tedizolid for the Management of Human Infections: In Vitro CharacteristicsClinical Infectious Diseases, 2014
- In Vitro Activity of Amikacin against Isolates of Mycobacterium avium Complex with Proposed MIC Breakpoints and Finding of a 16S rRNA Gene Mutation in Treated IsolatesJournal of Clinical Microbiology, 2013
- Pharmacokinetics of Tedizolid Following Oral Administration: Single and Multiple Dose, Effect of Food, and Comparison of Two Solid Forms of the ProdrugPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2013
- Tedizolid (TR-701): a new oxazolidinone with enhanced potencyExpert Opinion on Investigational Drugs, 2012
- In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococciJournal of Antimicrobial Chemotherapy, 2011
- Phase 2, Randomized, Double-Blind, Dose-Ranging Study Evaluating the Safety, Tolerability, Population Pharmacokinetics, and Efficacy of Oral Torezolid Phosphate in Patients with Complicated Skin and Skin Structure InfectionsAntimicrobial Agents and Chemotherapy, 2011
- Activity of novel oxazolidinones against Nocardia brasiliensis growing within THP-1 macrophagesJournal of Antimicrobial Chemotherapy, 2009
- In Vitro Activities of DA-7157 and DA-7218 against Mycobacterium tuberculosis and Nocardia brasiliensisAntimicrobial Agents and Chemotherapy, 2006
- Successful Treatment of DisseminatedMycobacterium chelonaeInfection with LinezolidClinical Infectious Diseases, 2001